BioCryst Pharmaceuticals, Inc. (BCRX) vs Xeris Biopharma Holdings, Inc. (XERS)
- BioCryst Pharmaceuticals, Inc. BCRX 7.79 −2.87%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
BioCryst Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. BioCryst Pharmaceuticals, Inc. is the larger, with a market value of $2.1B against $1.8B — 1.1× the size. BioCryst Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 68.7% against 36.3%. Xeris Biopharma Holdings, Inc. has the higher net margin (−5.12% vs −40.9%) and the higher return on invested capital (18.9% vs −610.6%). Across the 18 metrics below, BioCryst Pharmaceuticals, Inc. leads on 11 and Xeris Biopharma Holdings, Inc. on 7.
Valuation
Profitability
| Metric | BCRX | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.78% | 86.58% | 53.94% |
| Operating margin | (33.29%) | 10.91% | 0.00% |
| Net margin | (40.90%) | (5.12%) | 0.00% |
| Free cash flow margin | 39.75% | 16.60% | 0.00% |
| Return on equity | 87.84% | 118.22% | (0.40%) |
| Return on assets | (75.79%) | (4.60%) | (3.32%) |
| Return on invested capital | (610.55%) | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack